Mental Health Matters
Medical Student Blogger
Resources Applying Medical School
Premed Motivation Instagram
CV building for Fellow Medical Students
SH: FEBRILE TOPICS OF DISCUION
Social History
Medscape's Jillian Mock's on Medical News
#MEDBIKINI: DOCTORS CALL OUT STUDY FOR SEXISM & DISCRIMINATION
The Washington Post
THE AFFORDABLE CARE ACT RETURNS TO THE SUPREME COURT IN THE SHADOW OF A PANDEMIC
Mental Health Matters
Medical Student Blogger
Resources Applying Medical School
Premed Motivation Instagram
CV building for Fellow Medical Students
PERTINENT FINDINGS IN HEALTHCARE TODAY
Why is this important?
In secondary applications and/or during an interview, many medical school applicants may be asked to discuss or comment on current issues and hot topics regarding the state of health care.
Joint release by the World Health Organization, United for Global Mental Health and the World Federation for Mental Health
GLOBAL CHALLENGE FOR MOVEMENT ON MENTAL HEALTH KICKS OFF AS LACK OF INVESTMENT IN MENTAL HEALTH LEAVES MILLIONS WITHOUT ACCESS TO SERVICES
Journal of General Internal Medicine
UNDERSTANDING AFRICAN AMERICANS' VIEWS OF THE TRUSTWORTHINESS OF PHYSICIANS
NOVEL CORONAVIRUS (COVID-19) RESOURCE PAGE
COVID-19 Burdens Follow Patients After Discharge
RACE & COVID-19: STARK DISPARITIES IN RURAL GEORGIA
JOHNS HOPKINS COVID-19 TRACKER BOARD
ASSESSING RISK FACTORS FOR SEVERE COVID-19 INFECTIONS
UNIVERSITY OF WASHINGTON IHME
COVID-19 PROJECTIONS
CC: COVID-19
Chief Complaint
FDA AUTHORIZES EMERGENCY USE FOR
ELI LILLY COVID-19 ANTIBODY TREATMENT
Reuters (11/9, Beasley) reports the Food and Drug Administration authorized on Monday emergency use of Eli Lilly’s “COVID-19 antibody treatment for non-hospitalized patients older than 65 or who have certain chronic medical conditions.” The FDA found that clinical trials indicated the treatment, bamlanivimab, “reduced the need for hospitalization or emergency room visits in high-risk COVID-19 patients.”
The AP (11/9, Perrone) reports the FDA “cleared the experimental drug from Eli Lilly for people 12 and older with mild or moderate COVID-19 not requiring hospitalization.” The treatment is administered once by means of an IV.
CNN (11/9, Fox, Christensen) reports the treatment “must be infused in a hospital or other health care setting” and “is the first monoclonal antibody to be authorized for use in treating coronavirus.”
NBC News (11/10, Edwards) reports that Eli Lilly “has already begun manufacturing the drug, and it said it could have as many as 1 million doses available by the end of the year.”